MRNA - Hot Stocks: COVID vaccine makers in focus; PTGX clinical hold; TMO guidance; data drives TCRR IPHA

COVID boost shots and drug development marked crucial themes in Friday's trading as a closely watched U.S. government panel met and backed a third COVID vaccine shot for certain Americans. COVID vaccine makers BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) all lost ground during the session amid uncertainty about what the U.S. Food and Drug Administration panel would ultimately decide about boosters. In the drug-development space, Protagonist Therapeutics (NASDAQ:PTGX) tumbled more than 60% after the FDA put a clinical hold on the firm's lead experimental candidate. TCR2 Therapeutics (NASDAQ:TCRR) also suffered a massive retreat, losing more than a third of its value on disappointing clinical-trial data. On the other side of the spectrum, Innate Pharma (NASDAQ:IPHA) continued its recent gains on the release of strong trial results. The stock has now more than doubled in a little more than two weeks. Sticking to the world of science, scientific instruments maker

For further details see:

Hot Stocks: COVID vaccine makers in focus; PTGX clinical hold; TMO guidance; data drives TCRR, IPHA